21 November 2024, Root, Switzerland-Novocure (NASDAQ: NVCR) showcased significant results regarding its Tumor Treating Fields (TTFields) therapy at the 29th Annual Society for Neuro-Oncology (SNO) Meeting held in Houston, Texas.
The company noted AI insights to increase treatment precision and glioblastoma outcomes.
The presentations incorporate information from a partnership with fixtures that employed AI to investigate real-world data of IDH-mutant glioblastoma patients.
“AI has also enabled us to identify trends which can assist in optimizing therapies and provide options to patients who had none before,”
Noted Jennifer M. Connelly Neurology Department Medical College of Wisconsin
Apart from other independent studies, Novocure demonstrated the effectiveness of its new Head Flexible Electrodes (HFE) transducer arrays for the treatment of infratentorial tumors.
“It was possible to improve the TTFields delivery by refining the design of electrodes thanks to AI-assisted modeling,”
Emphasized Dheeraj Bhavanasi, Researcher at Novocure.
The event includes over 20 independent studies evaluating TTFields, promising a move towards machine learning-aided personalized cancer treatment shortly.
“AI makes it possible for those researching to utilize preclinical information and give it clinical significance expediently”,
Said Moshe Giladi Scientist at Novocure Ltd.
AI’s pivotal position within oncology will be the subject of further discussion during Novocure’s sponsored symposium “From Evidence to Practice” on Friday, 22 November.
Latest Stories:
Fully Automated 5G Port Plans Unveiled by Singtel and Ericsson
What is your reaction?
